| Literature DB >> 28862683 |
Paulo F M Oliveira1,2,3, Brigitte Guidetti4,5, Alain Chamayou6, Christiane André-Barrès7,8, Jan Madacki9, Jana Korduláková10, Giorgia Mori11, Beatrice Silvia Orena12, Laurent Roberto Chiarelli13, Maria Rosalia Pasca14, Christian Lherbet15,16, Chantal Carayon17,18, Stéphane Massou19, Michel Baron20, Michel Baltas21,22.
Abstract
A series of isoniazid derivatives bearing a phenolic or heteroaromatic coupled frame were obtained by mechanochemical means. Their pH stability and their structural (conformer/isomer) analysis were checked. The activity of prepared derivatives against Mycobacterium tuberculosis cell growth was evaluated. Some compounds such as phenolic hydrazine 1a and almost all heteroaromatic ones, especially 2, 5 and 7, are more active than isoniazid, and their activity against some M. tuberculosis MDR clinical isolates was determined. Compounds 1a and 7 present a selectivity index >1400 evaluated on MRC5 human fibroblast cells. The mechanism of action of selected hydrazones was demonstrated to block mycolic acid synthesis due to InhA inhibition inside the mycobacterial cell.Entities:
Keywords: Mycobacterium tuberculosis; hydrazone; mechanochemistry
Mesh:
Substances:
Year: 2017 PMID: 28862683 PMCID: PMC6151834 DOI: 10.3390/molecules22091457
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.411
Figure 1Antitubercular drug Isoniazid (1952), and Bedaquiline and Delamanid, two new compounds approved for the treatment of MDR-TB.
Figure 2Isonicotinoyl hydrazones synthesized by co-grinding of isoniazide and an aldehyde.
Hydrazones 2–11 produced mechanochemically by reacting INH and imidazolic, indazolic or indolic aldehydes. The reaction was catalyzed by p-TSA.
| Aldehydes | Heterocyclic Hydrazones (6) Derived From Isoniazid | |
|---|---|---|
| Imidazole derivatives | ||
| Indazole derivatives | ||
| Indole derivatives | ||
[a] Yields after washing with NaHCO3 aqueous solution to eliminate p-TSA. According to TLC, 1H-NMR and MS, the conversions were quantitative.
Figure 3E/Z-configurational isomers and cis/trans amide conformers for N-acylhydrazones.
Geometries and energies of minima and transition state for cis and trans E-isomers of 1a obtained at B3LYP/6-31+G(d,p) level in the gas phase and using the DMSO polarizable continuum model (SMD).
| −816.730569 | −816.553707 | 1.47 | 8 | |
| −816.733307 | −816.55605 | 0 | 92 | |
| −816.763427 | −816.585816 | −1.68 | 94 | |
| −816.761415 | −816.583145 | 0 | 6 | |
| TS_ | −816.765271 | −816.557724 | 17.63 | - |
Geometries, Gibbs free energies and Boltzmann distribution of the four major conformers of 5 at the B3LYP/6-31+G(d,p) in the gas phase and in the DMSO continuum solvent model (SMD).
| Isomer | Geometry ( | G ( | % | G ( | % |
|---|---|---|---|---|---|
| −888.90736 | 0.34 | −888.94471 | 28.22 | ||
| −888.909926 | 5.09 | −888.94528 | 51.50 | ||
| −888.910465 | 9.0 | −888.941968 | 1.54 | ||
| −888.912591 | 85.6 | −888.944326 | 18.72 |
Stability study of hydrazones.
| Compound | Medium | Conc. (mol/L) | pH | Time | Stability |
|---|---|---|---|---|---|
| 28% EtOH/H2O | 6.0 × 10−5 | 6.1 | 22 h | stable | |
| 6.3 × 10−5 | 6.5 | 22 h | stable | ||
| 6.9 × 10−5 | 6.3 | 15 h | stable | ||
| 5.9 × 10−5 | 6.2 | 21 h | stable | ||
| 5% EtOH/PIPES buffer (50 mM) | 4.1 × 10−5 | 6.8 | 20 h | 3% Abs. reduction | |
| 3.1 × 10−5 | 6.8 | 20 h | stable | ||
| 7 days | 5% Abs. reduction |
Figure 4Protonation states of the hydrazone 1d as function of pH.
Figure 5The variations on the UV-vis spectra for compound 1d and the resulting plot for six wavelength values. (a) UV-vis spectra obtained for compound 1d as function of pH variation; (b) Plots of absorbance for six wavelength values (λ/nm) as function of pH for compound 1d.
pKa values determined for the isonicotinoylhydrazones.
| Compound | 1a | 1b | 1c | 1d | 5 | 7 |
|---|---|---|---|---|---|---|
| p | nd a | nd a | 3.4 | 3.0 | 3.4 | 3.6 |
| p | 9.2 ± 0.1 | 7.4 ± 0.1 | 9.1 ± 0.1 | 9.5 ± 0.1 | 10.4 ± 0.1 | 11 |
| p | - | 8.9 ± 0.1 | - | >11 | - | - |
a nd for not determined.
Enzyme inhibition values for the INH derivatives. Results are expressed as a percentage of InhA inhibition.
| Compound | % Inhibition at 50 μM (Inhibitor) | Compound | % Inhibition at 50 μM (Inhibitor) |
|---|---|---|---|
| 45 | 19 | ||
| 54 | 43 | ||
| 48 | 39 | ||
| 64 | 42 | ||
| 54 | 32 | ||
| 3 | 79 | ||
| 33 | not soluble | ||
| >99 |
Phenolic isonicotinoyl hydrazones tested as inhibitory agents against M.tb growth (H37Rv strain).
| Compound | MW (g/mol) | MIC (μg/mL)/(μM) | LogP | Cpd | MW (g/mol) | MIC (μg/mL)/(μM) | LogP |
|---|---|---|---|---|---|---|---|
| 241.25 | 0.0125/0.05 | 1.64 | 271.27 | 0.125/0.46 | 1.51 | ||
| 257.24 | 0.125/0.49 | 1.25 | 301.30 | 0.125/0.41 | 1.38 | ||
| 137.14 | 0.025/0.18 | −0.64 |
MICs of Isoniazid-Nitrogen heterocyclic hydrazones against M.tb H37Rv.
| Compound | MW (g/mol) | MIC (μg/mL)/(μM) | LogP | Cpd | MW (g/mol) | MIC (μg/mL)/(μM) | LogP |
|---|---|---|---|---|---|---|---|
| 215.21 | 0.03/0.14 | −1.00 | 265.27 | 0.015/0.056 | 0.24 | ||
| 229.24 | 0.03/0.13 | −1.37 | 264.28 | 0.06/0.23 | 0.86 | ||
| 265.27 | 0.06/0.23 | 1.38 | 343.18 | 0.125/0.36 | 1.69 | ||
| 265.27 | 0.03/0.11 | −0.52 | 264.28 | 0.06/0.23 | 0.52 | ||
| 278.31 | 0.25/0.90 | 0.49 | 309.28 | 0.25/0.81 | 1.39 | ||
| 137.14 | 0.05/0.36 | −0.64 |
MIC of isoniazid derivatives against M.tb MDR isolate IC2.
| Compound | MIC (μg/mL)/(μM) | |
|---|---|---|
| H37Rv | IC2 | |
| 0.0125/0.05 | 2.5/10.36 | |
| 0.125/0.49 | 1/3.89 | |
| 0.125/0.46 | >2.5/>9.22 | |
| 0.125/0.41 | >2.5/>8.30 | |
| 0.03/0.14 | 5/23.2 | |
| 0.03/0.13 | 5–10/21.8–43.6 | |
| 0.06/0.23 | >10 | |
| 0.03/0.11 | >10 | |
| 0.25/0.90 | >10 | |
| 0.015/0.056 | >10 | |
| 0.06/0.23 | >10 | |
| 0.125/0.36 | >10 | |
| 0.06/0.23 | >10 | |
| 0.25/0.81 | 5–10/18.9–37.8 | |
| 0.025/0.18 | >2/>14.58 | |
Cytotoxicity (LD50) and selectivity index (SI) for the most active hydrazones against H37Rv M.tb.
| Compound | LD50 (μM) | SI | Compound | LD50 (μM) | SI |
|---|---|---|---|---|---|
| >80 | >1600 | >80 | >727 | ||
| 36.3 | 74 | 129 | 143 | ||
| >80 | >173 | >80 | >1429 | ||
| >80 | >195 | >80 | >364 | ||
| >80 | >571 | >80 | >222 | ||
| >80 | >615 | 71.4 | 310 | ||
| >80 | >364 | 156 | 193 | ||
| - | - |
Figure 6TLC analysis of lipids extracted from 14C acetate labeled M.tb H37Ra cells treated with compounds 1a, 3, 5, 7 and 10, INH and DMSO as a control. Lipids were separated in chloroform:methanol:water (20:4:0.5) and detected by autoradiography (TDM: trehalose dimycolates; TMM: trehalose monomycolates; PE: phosphatidylethanolamine; CL: cardiolipin).
Figure 7TLC analysis of methyl esters of fatty (FAME) and mycolic (MAME) acids isolated from 14C acetate labeled M.tb H37Ra cells treated with compounds 1a, 3, 5, 7 and 10, INH and DMSO as a control. Different forms of methyl esters were separated in n-hexane:ethyl acetate (95:5; 3×) and detected by autoradiography. (α, methoxy, and keto refer to forms of MAMEs).
Figure 8Determination of sensitivity of M.tb H37Ra pMV261 and M.tb H37Ra pMV261-InhA against 1a (Left panel) and 3, 5, 7 and 10 (Right panel) by drop dilution method.